Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014014 · ClinicalTrials.gov registry record · Phase 1
Zidovudine and Lamivudine Given Once Versus Twice Daily
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT00014014 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00014014, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if the full daily dose of Combivir (zidovudine \[ZDV\]/lamivudine \[3TC\]) taken once a day is as effective as the usual recommended twice-a-day dose. Studies have shown that the antiviral activity of ZDV can continue in the body even after there does not appear to be any ZDV left in the blood. This occurs because the body breaks down the drug into substances that remain active against HIV. The body also breaks down 3TC, a drug that is combined with ZDV in the Combivir product, in a similar way. Since antiviral activity may continue after Combivir is removed from the body, it may not be necessary to take the drug as often as once thought. This study carefully measures levels of the active substances in order to find out whether the same amount of antiviral activity occurs with less-frequent dosing.
Conditions Studied
Interventions
- DRUG Lamivudine/Zidovudine
Study Locations (20)
Illinois
- Mt Sinai Hosp Med Ctr / Dept of Pediatrics - Chicago
- Cook County Hosp - Chicago
- Chicago Children's Memorial Hosp - Chicago
New York
- Metropolitan Hosp Ctr - New York
- State Univ of New York at Stony Brook - Stony Brook
- SUNY Health Sciences Ctr at Syracuse / Pediatrics - Syracuse
California
- Los Angeles County - USC Med Ctr - Los Angeles
- Univ of California, San Diego - San Diego
New Jersey
- Univ of Medicine & Dentistry of New Jersey / Univ Hosp - Newark
- St Joseph's Hosp & Med Center - Paterson
Pennsylvania
- Children's Hosp of Philadelphia - Philadelphia
- Temple University School of Medicine - Philadelphia
Florida
- Univ of Florida Health Science Ctr / Pediatrics - Jacksonville
Georgia
- Emory Univ Hosp / Pediatrics - Atlanta
Louisiana
- Tulane Univ / Charity Hosp of New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014014
The ClinicalTrials.gov registry entry for NCT00014014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Lamivudine/Zidovudine is the first listed.
NCT00014014 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Illinois, New York, California.
Frequently Asked Questions
What is clinical trial NCT00014014 about?
NCT00014014 is a clinical study titled "Zidovudine and Lamivudine Given Once Versus Twice Daily". The purpose of this study is to see if the full daily dose of Combivir (zidovudine \[ZDV\]/lamivudine \[3TC\]) taken once a day is as effective as the usual recommended twice-a-day dose. Studies have shown that the antiviral activity of ZDV can continue in the body even after there does not appear ...
What is the current status of trial NCT00014014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. Estimated completion is 2002-08.
What conditions does trial NCT00014014 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00014014?
The interventions under investigation include: Lamivudine/Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00014014?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00014014 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.